TY - JOUR
T1 - Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
AU - Vermunt, Lisa
AU - Sikkes, Sietske A M
AU - van den Hout, Ardo
AU - Handels, Ron
AU - Bos, Isabelle
AU - van der Flier, Wiesje M
AU - Kern, Silke
AU - Ousset, Pierre-Jean
AU - Maruff, Paul
AU - Skoog, Ingmar
AU - Verhey, Frans R J
AU - Freund-Levi, Yvonne
AU - Tsolaki, Magda
AU - Wallin, Åsa K
AU - Olde Rikkert, Marcel
AU - Soininen, Hilkka
AU - Spiru, Luisa
AU - Zetterberg, Henrik
AU - Blennow, Kaj
AU - Scheltens, Philip
AU - Muniz-Terrera, Graciela
AU - Visser, Pieter Jelle
AU - Alzheimer Disease Neuroimaging Initiative
A2 - Waldemar, Gunhild
N1 - Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
PY - 2019/7
Y1 - 2019/7
N2 - INTRODUCTION: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration.METHODS: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration.RESULTS: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage.DISCUSSION: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.
AB - INTRODUCTION: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration.METHODS: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration.RESULTS: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage.DISCUSSION: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.
U2 - 10.1016/j.jalz.2019.04.001
DO - 10.1016/j.jalz.2019.04.001
M3 - Journal article
C2 - 31164314
SN - 1552-5260
VL - 15
SP - 888
EP - 898
JO - Alzheimer's & dementia : the journal of the Alzheimer's Association
JF - Alzheimer's & dementia : the journal of the Alzheimer's Association
IS - 7
ER -